The 2022 ASCO Annual Meeting, held in Chicago, IL showcased the latest research in cancer care. This year's programme featured several sessions complementing the meeting's theme: Advancing Equitable Cancer Care Through Innovation. Key trial updates include the practice-changing results of DESTINY-Breast04, PARADIGM as well as the novel KRASG12C inhibitor adagrasib, in non-small cell lung cancer.
View all videos

ASCO 2022

American Society for Clinical Oncology Annual Meeting 2022
03–07 June 2022 | Chicago, IL, and Online
VJOncologyVJ Oncology@VJOncology·
April 1, 2023

#GDUGI2023 has wrapped!

http://VJOncology.com will have highlights of radiation therapy in borderline-resectable pancreatic cancer and more GI oncology from the final day of debates and updates ℹ️📽️

@GreatDebatesCME #CRCSM #PancSM #ESOCSM #STCSM #HPBCSM

Reply on Twitter 1642200195843735552Retweet on Twitter 1642200195843735552Like on Twitter 16422001958437355521Twitter 1642200195843735552
VJOncologyVJ Oncology@VJOncology·
April 1, 2023

🎥 Andreas Dietz of @UniLeipzig discusses highlights from ECHNO 2023

Watch: 👉http://ow.ly/VOxt50NwT9M👈

@EHNSnews #ECHNO2023 #hncsm #HeadAndNeckCancer

Reply on Twitter 1642177541820633095Retweet on Twitter 1642177541820633095Like on Twitter 16421775418206330953Twitter 1642177541820633095
Retweet on TwitterVJ Oncology Retweeted
montypalSumanta K. Pal, MD, FASCO@montypal·
March 31, 2023

My dear friend & former coresident at @UCLA @datsunian put together this terrific summary for the @ASCO Daily News summarizing the link between ICIs & CVD. A critical message - plz read & pass along! @DrChoueiri @neerajaiims @avirupguha @CardioOncology @ACCinTouch @PGrivasMDPhD https://twitter.com/asco/status/1641533259103215616

ASCO@ASCO

[email protected] and @datsunian of @UCLAHealth explore the emerging link between immune checkpoint inhibitor cancer therapies and cardiovascular adverse events: https://fal.cn/3x11J #ASCODailyNews #CardioOnc

Reply on Twitter 1641796231939899392Retweet on Twitter 164179623193989939216Like on Twitter 164179623193989939252Twitter 1641796231939899392
VJOncologyVJ Oncology@VJOncology·
April 1, 2023

This week's podcast is on highlights in #BreastCancer from St Gallen BCC 👩‍⚕️

Find out the latest in the use of chemotherapy, post-adjuvant therapy, clinical trial ethics, and more!

Listen here: 🎧http://ow.ly/encr50NwSWS

@DrLisaCarey @hoperugo @stolaney1 @lab_kok @KaidarOrit

Reply on Twitter 1642086945680392192Retweet on Twitter 1642086945680392192Like on Twitter 16420869456803921924Twitter 1642086945680392192
VJOncologyVJ Oncology@VJOncology·
April 1, 2023

🚨 It’s the last day of #ELCC23 ! We’ll be bringing you the latest news on what experts have been discussing in #LungCancer as the event concludes!

Keep up-to-date at http://VJOncology.com

@VJOncology @myESMO #ELCC23 @OncoAlert #LCsm

Reply on Twitter 1642044272596643842Retweet on Twitter 1642044272596643842Like on Twitter 16420442725966438425Twitter 1642044272596643842
Load More

ASCO 2022

American Society for Clinical Oncology Annual Meeting 2022
03–07 June 2022 | Chicago, IL, and Online
The 2022 ASCO Annual Meeting, held in Chicago, IL showcased the latest research in cancer care. This year's programme featured several sessions complementing the meeting's theme: Advancing Equitable Cancer Care Through Innovation. Key trial updates include the practice-changing results of DESTINY-Breast04, PARADIGM as well as the novel KRASG12C inhibitor adagrasib, in non-small cell lung cancer.
View all videos
VJOncologyVJ Oncology@VJOncology·
April 1, 2023

#GDUGI2023 has wrapped!

http://VJOncology.com will have highlights of radiation therapy in borderline-resectable pancreatic cancer and more GI oncology from the final day of debates and updates ℹ️📽️

@GreatDebatesCME #CRCSM #PancSM #ESOCSM #STCSM #HPBCSM

Reply on Twitter 1642200195843735552Retweet on Twitter 1642200195843735552Like on Twitter 16422001958437355521Twitter 1642200195843735552
VJOncologyVJ Oncology@VJOncology·
April 1, 2023

🎥 Andreas Dietz of @UniLeipzig discusses highlights from ECHNO 2023

Watch: 👉http://ow.ly/VOxt50NwT9M👈

@EHNSnews #ECHNO2023 #hncsm #HeadAndNeckCancer

Reply on Twitter 1642177541820633095Retweet on Twitter 1642177541820633095Like on Twitter 16421775418206330953Twitter 1642177541820633095
Retweet on TwitterVJ Oncology Retweeted
montypalSumanta K. Pal, MD, FASCO@montypal·
March 31, 2023

My dear friend & former coresident at @UCLA @datsunian put together this terrific summary for the @ASCO Daily News summarizing the link between ICIs & CVD. A critical message - plz read & pass along! @DrChoueiri @neerajaiims @avirupguha @CardioOncology @ACCinTouch @PGrivasMDPhD https://twitter.com/asco/status/1641533259103215616

ASCO@ASCO

[email protected] and @datsunian of @UCLAHealth explore the emerging link between immune checkpoint inhibitor cancer therapies and cardiovascular adverse events: https://fal.cn/3x11J #ASCODailyNews #CardioOnc

Reply on Twitter 1641796231939899392Retweet on Twitter 164179623193989939216Like on Twitter 164179623193989939252Twitter 1641796231939899392
VJOncologyVJ Oncology@VJOncology·
April 1, 2023

This week's podcast is on highlights in #BreastCancer from St Gallen BCC 👩‍⚕️

Find out the latest in the use of chemotherapy, post-adjuvant therapy, clinical trial ethics, and more!

Listen here: 🎧http://ow.ly/encr50NwSWS

@DrLisaCarey @hoperugo @stolaney1 @lab_kok @KaidarOrit

Reply on Twitter 1642086945680392192Retweet on Twitter 1642086945680392192Like on Twitter 16420869456803921924Twitter 1642086945680392192
VJOncologyVJ Oncology@VJOncology·
April 1, 2023

🚨 It’s the last day of #ELCC23 ! We’ll be bringing you the latest news on what experts have been discussing in #LungCancer as the event concludes!

Keep up-to-date at http://VJOncology.com

@VJOncology @myESMO #ELCC23 @OncoAlert #LCsm

Reply on Twitter 1642044272596643842Retweet on Twitter 1642044272596643842Like on Twitter 16420442725966438425Twitter 1642044272596643842
Load More

Late-Breaking Abstracts at ASCO 2022!

View all
1:28
PARADIGM: panitumumab superior to bevacizumab as 1L treatment of patients with RAS WT mCRC
Takayuki Yoshino • 5 Jun 2022
2:19
Final results from ATLANTIS cabozantinib arm for urothelial carcinoma
Robert Jones • 4 Jun 2022
1:22
KRYSTAL-1: activity and safety of adagrasib in patients with advanced/metastatic KRASG12Cm NSCLC
Alexander Spira • 3 Jun 2022
5:11
DESTINY-Breast04: T-DXd provides significant improvement in OS + PFS in HER2-low mBC
Hope Rugo • 5 Jun 2022

Latest videos from ASCO 2022

View all
1:32
Key trials in prostate cancer at ASCO 2022
Arun Azad • 27 May 2022
2:35
Adjuvant therapy in RCC: harnessing prognostic information
Pavlos Msaouel • 3 Jun 2022
1:22
KRYSTAL-1: activity and safety of adagrasib in patients with advanced/metastatic KRASG12Cm NSCLC
Alexander Spira • 3 Jun 2022
0:49
Current standards in BCG-unresponsive carcinoma in-situ and papillary NMIBC
Karim Chamie • 3 Jun 2022

Breast Cancer at ASCO 2022

View all
0:51
What to look forward to in breast cancer at ASCO 2022?
Kevin Kalinsky • 3 Jun 2022
0:53
postMONARCHE: abemaciclib + fulvestrant in HR+/HER2- MBC following CDK4/6i & endocrine therapy
Kevin Kalinsky • 3 Jun 2022
1:46
ctDNA and late recurrence in high-risk, HR+, HER2- breast cancer
Marla Lipsyc-Sharf • 4 Jun 2022
0:48
MAINTAIN: fulvestrant or exemestane +/- ribociclib after anti-estrogen therapy + CDK4/6i in HR+ MBC
Kevin Kalinsky • 3 Jun 2022

GU at ASCO 2022

View all
1:32
Key trials in prostate cancer at ASCO 2022
Arun Azad • 27 May 2022
0:49
Current standards in BCG-unresponsive carcinoma in-situ and papillary NMIBC
Karim Chamie • 3 Jun 2022
2:19
Final results from ATLANTIS cabozantinib arm for urothelial carcinoma
Robert Jones • 4 Jun 2022
1:12
JAVELIN Bladder 100: Avelumab maintenance for metastatic or locally advanced bladder cancer
Joaquim Bellmunt • 4 Jun 2022
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals